BioNTech (NASDAQ:BNTX) Shares Gap Down – Time to Sell?

BioNTech SE (NASDAQ:BNTX)’s stock price gapped down before the market opened on Monday . The stock had previously closed at $94.95, but opened at $89.00. BioNTech shares last traded at $87.78, with a volume of 388,763 shares traded.

Analyst Ratings Changes

A number of brokerages have recently weighed in on BNTX. Truist Financial initiated coverage on BioNTech in a research note on Friday, January 10th. They issued a “buy” rating and a $172.00 price objective for the company. Morgan Stanley dropped their target price on BioNTech from $145.00 to $139.00 and set an “overweight” rating for the company in a research report on Tuesday, March 11th. Citigroup started coverage on shares of BioNTech in a research report on Thursday, March 13th. They set a “buy” rating and a $145.00 price target on the stock. Canaccord Genuity Group restated a “buy” rating and issued a $171.44 price objective on shares of BioNTech in a report on Tuesday, March 11th. Finally, BMO Capital Markets upped their target price on shares of BioNTech from $130.00 to $143.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 11th. Three equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $143.73.

BioNTech Trading Down 6.8 %

The company has a market cap of $21.24 billion, a price-to-earnings ratio of -42.14 and a beta of 0.30. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The business’s fifty day simple moving average is $111.41 and its two-hundred day simple moving average is $113.74.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Monday, March 10th. The company reported $1.08 EPS for the quarter, topping the consensus estimate of $0.38 by $0.70. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.24 billion. During the same period last year, the business earned $1.90 EPS. BioNTech’s revenue for the quarter was down 19.5% compared to the same quarter last year. On average, equities analysts predict that BioNTech SE will post -3.88 EPS for the current year.

Institutional Trading of BioNTech

Large investors have recently made changes to their positions in the company. Jones Financial Companies Lllp lifted its stake in BioNTech by 110.3% in the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock valued at $53,000 after buying an additional 246 shares during the last quarter. Quintet Private Bank Europe S.A. boosted its stake in BioNTech by 823.5% during the 4th quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company’s stock worth $88,000 after purchasing an additional 700 shares during the period. Allianz SE purchased a new position in BioNTech during the 4th quarter worth $90,000. GAMMA Investing LLC increased its stake in BioNTech by 48.2% in the fourth quarter. GAMMA Investing LLC now owns 923 shares of the company’s stock valued at $105,000 after purchasing an additional 300 shares during the period. Finally, Generali Investments CEE investicni spolecnost a.s. purchased a new stake in shares of BioNTech in the fourth quarter valued at about $137,000. 15.52% of the stock is owned by institutional investors and hedge funds.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.